CLOCK and ovarian carcinoma: This study aims to investigate circadian clock-associated alterations in patients with high-grade ovarian cancer undergoing maintenance therapy with rucaparib vs. placebo following platinum-based chemotherapy and bevacizumab maintenance therapy as part of the MAMOC clinical trial, and how circadian rhythms disruptions may inform chronotherapy strategies in ovarian cancer treatment.